Canntab Receives Health Canada Licence and Closes $3.08M Offering
Canntab Therapeutics Limited, the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to announce that on Friday, February 28th, 2020 it successfully received its Cannabis Standard Processing & Sales for Medical Purposes Licences from Health Canada, and that it has closed the first tranche of its non-brokered private placement offering for total gross proceeds of $3,080,000.
"With the licensing and financing, we are now in a position to move into full scale manufacturing and distribution of our next generation of biopharmaceutical cannabinoid solutions. We plan to roll-out new brands and products for sale, starting this summer," explains Jeff Renwick, Chief Executive Officer at Canntab. "Canntab intends to be the first to bring timed-release cannabinoid hard pills to market in Canada," concludes Renwick.
Follow us on Instagram
Connect with us on Linkedin